LuCAB: A Phase I/II trial evaluating cabazitaxel in combination with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer

被引：0
|
作者：
Kostos, Louise [1 ,2 ]
Buteau, James P. [2 ,3 ]
Kong, Grace [2 ,3 ]
Opar, Petra [4 ]
Di Lulio, Juliana [4 ]
Fahey, Michael [4 ]
Fettke, Heidi [2 ,3 ]
Furic, Luc [3 ,5 ]
Hofman, Michael S. [2 ,3 ]
Azad, Arun [2 ,3 ]
机构：
[1] Peter MacCallum Canc Ctr, Dept Med Oncol, Box Hill, Vic, Australia
[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[4] Peter MacCallum Canc Ctr, Ctr Biostat & Clin Trials, Melbourne, Vic, Australia
[5] Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
abs39
引用
收藏
页码：77 / 77
页数：1
相关论文
共 50 条
  • [41] Comment on, 177Lu-PSMA-617 in metastatic, castration-resistant prostate cancer"
    Radtke, Jan Philipp
    Albers, Peter
    Giesel, Frederik Lars
    AKTUELLE UROLOGIE, 2022, 53 (02)
  • [42] Prognostic Value of the De Ritis Ratio for Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Radioligand Therapy
    Gaal, Sebastian
    Huang, Kai
    Rogasch, Julian M. M.
    Jochens, Hans V.
    De Santis, Maria
    Erber, Barbara
    Amthauer, Holger
    CANCERS, 2023, 15 (20)
  • [43] Building a predictive model for outcomes with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer using VISION data: Preliminary results.
    Herrmann, Ken
    Gafita, Andrei
    De Bono, Johann S.
    Sartor, A. Oliver
    Chi, Kim N.
    Krause, Bernd J.
    Rahbar, Kambiz
    Tagawa, Scott T.
    Czernin, Johannes
    El-Haddad, Ghassan
    Wong, Connie
    Zhang, Zhaojie
    Wilke, Celine
    Mirante, Osvaldo
    Morris, Michael J.
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 208 - 208
  • [44] VISION trial: 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer
    Rohith, Gorrepati
    INDIAN JOURNAL OF UROLOGY, 2021, 37 (04) : 372 - 373
  • [45] Genomic aberrations in circulating tumor DNA (ctDNA) and clinical outcomes from [177Lu] Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC)
    Fettke, Heidi
    Kostos, Louise
    Buteau, James
    Steen, Jason A.
    Medhurst, Elizabeth
    Haskali, Mo B.
    Murphy, Declan
    Docanto, Maria
    Bukczynska, Patricia
    Ng, Nicole
    Sandhu, Shahneen
    Foroughi, Siavash
    Furic, Luc
    Nguyen-Dumont, Tu
    Hofman, Michael S.
    Azad, Arun A.
    CANCER RESEARCH, 2023, 83 (07)
  • [46] Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617
    Justin Ferdinandus
    John Violet
    Shahneen Sandhu
    Rodney J. Hicks
    Aravind S. Ravi Kumar
    Amir Iravani
    Grace Kong
    Tim Akhurst
    Sue Ping Thang
    Declan G. Murphy
    Scott Williams
    Michael S. Hofman
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 2322 - 2327
  • [47] Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617
    Ferdinandus, Justin
    Violet, John
    Sandhu, Shahneen
    Hicks, Rodney J.
    Ravi Kumar, Aravind S.
    Iravani, Amir
    Kong, Grace
    Akhurst, Tim
    Thang, Sue Ping
    Murphy, Declan G.
    Williams, Scott
    Hofman, Michael S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (10) : 2322 - 2327
  • [48] Multi- cycle dosimetry of [177Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: results from the VISION trial sub-study
    Kurth, J.
    Rahbar, K.
    Eiber, M.
    Sparks, R.
    Baca, N.
    Krause, B. J.
    Lassmann, M.
    Jentzen, W.
    Chicco, D.
    Klein, P.
    Blumenstein, L.
    Basque, J.
    Herrmann, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S129 - S129
  • [49] [177Lu]Lu-PSMA-617 Versus Docetaxel in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: Final Survival Analysis of a Phase 2 Randomized, Controlled Trial
    Satapathy, Swayamjeet
    Mittal, Bhagwant Rai
    Sood, Ashwani
    Das, Chandan Krushna
    Mavuduru, Ravimohan Suryanarayan
    Goyal, Shikha
    Shukla, Jaya
    Singh, Shrawan Kumar
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (11) : 1726 - 1729
  • [50] Tumour dosimetry across 6 cycles of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: results from the VISION sub-study
    Herrmann, K.
    Krause, B.
    Chi, K.
    Sartor, O.
    Fizazi, K.
    Morris, M. J.
    De Bono, J.
    Tagawa, S.
    Kurth, J.
    Eiber, M.
    Lassmann, M.
    Jentzen, W.
    Sparks, R.
    Nguyen, Q.
    Blumentstein, L.
    Klein, P.
    Wilke, C.
    Rahbar, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S278 - S279
12345